CLP-d2 is a multi-target anti-inflammatory agent, osteoclastogenesis inhibitor, and immunomodulator with pharmacokinetic properties superior to Daptomycin and excellent safety. It reduces c-Fos and NFATc1 expression levels, decreases phosphorylation of IκBα, p65, ERK, and JNK, and inhibits the NF-κB and MAPK signaling pathways, thereby reducing the secretion of pro-inflammatory cytokines such as IL-6, TNF-α, and IL-1β, demonstrating anti-inflammatory activity. CLP-d2 inhibits osteoclast formation within mouse joints, alleviating bone erosion and joint swelling, reducing synovial hyperplasia and inflammatory cell infiltration, and lowering serum rheumatoid factor (RF) levels. It is applicable for research related to rheumatoid arthritis.